Amphotericin B ( DrugBank: Amphotericin B )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
299	Cystic fibrosis	2

299. Cystic fibrosis

---

Clinical trials : 1,695 /  Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02273661 (ClinicalTrials.gov)	November 19, 2014	22/10/2014	Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).	Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded)	Allergic Bronchopulmonary Aspergillosis	Drug: Liposomal amphotericin B (Ambisome®);Drug: placebo	Poitiers University Hospital	NULL	Completed	18 Years	N/A	All	174	Phase 2	France
2	EUCTR2010-019194-15-IT (EUCTR)	12/05/2010	13/05/2010	Esplorative study to evaluate the tolerability of Amphotericin B lipid complex (Abelcet) by aerosol in patients with Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis (ABPA) - ND	Esplorative study to evaluate the tolerability of Amphotericin B lipid complex (Abelcet) by aerosol in patients with Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis (ABPA) - ND	Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis (ABPA) MedDRA version: 9.1;Level: SOC;Classification code 10021881 MedDRA version: 9.1;Level: PT;Classification code 10011762	Trade Name: ABELCET INN or Proposed INN: Amphotericin B	AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy